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Abstract
Purpose We performed a retrospective analysis of patients treated with radical cystectomy and lymphadenectomy 
(LAD) for bladder cancer to assess the differential association of the extent of LAD with perioperative complications and 
re-hospitalization.
Materials and methods LAD templates were defined as limited (lLAD = external, internal iliac and obturator), extended 
(eLAD = up to crossing of ureter and presacral lymph nodes), and super-extended (sLAD = up to the inferior mesenteric 
artery). Logistic regression models investigated the association of LAD templates with intraoperative, 30- and 30–90-day 
postoperative complications, as well as re-hospitalizations within 30 and 30–90 days.
Results A total of 284 patients were available for analysis. sLAD led to a higher lymph-node yield (median 39 vs 13 for 
lLAD and 31 for eLAD, p < 0.05) and N2/N3 status compared to lLAD and eLAD (p = 0.04). sLAD was associated with 
a blood loss of > 500 ml (OR 1.3, 95% CI 1.08–1.49, p = 0.003) but not with intraoperative transfusion, operation time, or 
length of hospital stay (p > 0.05). Overall, 11 (4%) patients were readmitted within 30 days and 50 (17.6%) within 30–90 
days. The 30- and 30–90-day mortality rates were 2.8% and 1.4%, respectively. On logistic regression, LAD template was 
not associated with postoperative complications or re-hospitalization rates.
Conclusions sLAD leads to higher lymph-node yield and N2/N3 rate but not to higher complication rate compared to lLAD 
and eLAD. With the advent of novel adjuvant systemic therapies, precise nodal staging will have a crucial role in patients 
counseling and clinical decision making.
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Introduction
Radical cystectomy (RC) with lymphadenectomy (LAD), 
preceded by neoadjuvant chemotherapy (NAC) when pos-
sible, is the standard of care for muscle-invasive and recur-
rent high-risk bladder cancer (BCa) [1]. A properly done 
LAD allows accurate staging and may improve oncologic 
outcomes, since lymph-node metastases are present in up 
to 25% of patients treated with RC for muscle-invasive BCa 
[2–4]. However, the extent of LND is still under debate and 
the association of the extent of the LND templates with sur-
vival remains controversial [5]. In particular, the benefits of 
a super-extended LAD (sLAD) are questioned, as lymph-
node metastasis above the aortic bifurcation is uncommon 
and the dissection of these nodes could result in longer 
operative times. Indeed, adverse events and increased com-
plications can occur more frequently in more extensive LAD 
templates, potentially compromising quality of life in this 
population that is elderly in general [6–10]. The association 
of a more extensive LAD template with perioperative com-
plications has not been sufficiently assessed, to our knowl-
edge. Results from a recent randomized trial failed to show 
any significant differences in 30- and 90-day complications 
rates between extended LAD (eLAD) and sLAD [10]. How-
ever, this study did not report intraoperative complications 
and re-hospitalization rates. We hypothesized that a more 
extended LND would be associated with a higher rate of 
intra- and postoperative complications, length of stay, and 
re-admissions. To address this, we performed a detailed 
analysis of perioperative complications and investigated 
their association with different LAD templates.
Materials and methods
Patient selection
Following institutional review board approval (ID 
2168/2017), we reviewed our institutional database to iden-
tify patients treated with RC and LAD for clinically non-
metastatic BCa. Patients were considered non-metastatic if 
preoperative imaging did not show spread from the primary 
site to other places in the body. Patients with missing infor-
mation regarding postoperative complications within 90 
days and those who did not receive all oncologic care at our 
institution were excluded from the analysis.
Intervention and pathological analysis
Patients were treated with RC and LAD according to guide-
line recommendations at the time [1]. RC was performed 
by different surgeons. All procedures were performed by an 
open technique. The decision for the type of urinary diver-
sions was based on disease characteristics, patient’s wishes, 
and performance status. The extent of LAD was at the sur-
geon’s discretion. We defined 12 LAD regions. The limited 
template (lLAD) included bilateral internal iliacs, external 
iliacs, and obturator regions; the extended template (eLAD) 
included lLAD plus up to the crossing of the ureter on the 
common iliac vessels and presacral region; and the super-
extended template (sLAD) included the eLAD plus up to 
the inferior mesenteric artery in addition to, paracaval and 
para-aortal regions (Fig. 1). Specimens were analyzed by 
two dedicated genitourinary pathologists.
Follow‑up
Due to the retrospective nature of the study, the follow-up 
was not standardized, but was in accordance with the guide-
lines at the time. In general, patients underwent physical 
examination, ultrasonography, whole body imaging includ-
ing CT with contrast or MRI as well as bone scan when 
indicated, and laboratory testing and at physician discretion 
based on patient and disease risk. Postoperative complica-
tions were assessed using the Clavien–Dindo classification 
[11]. Complications were recorded within 30 days after 
surgery and between 31 and 90 days after surgery. Major 
complications were defined as Clavien–Dindo ≥ 3. Cause of 
Fig. 1  Anatomic template for lymph-node dissection. Limited tem-
plate included internal iliac, external iliac, and obturator region 
(7–12). Extended template additionally included common iliac 
and presacral region (4–12). Super-extended template additionally 
included inferior mesenteric artery, paracaval, and para-aortal region 
(1–12)
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death was recorded based on chart and/or death certificate 
review [12].
Statistical analyses
Means and standard deviations or median and interquartile 
range values are reported for normally or non-normally 
distributed continuous variables, respectively. Differences 
between proportions were reported using the Chi-square and 
the Mann–Whitney U test. We built logistic regression mod-
els to investigate the association of major postoperative com-
plications as well as intraoperative complications with the 
LAD template used. Statistical significance was considered 
at a p < 0.05. All tests were two-sided. Statistical analyses 
were performed using R (R project, Vienna, Austria).
Results
We identified 434 patients treated with RC within our insti-
tutional database. A total of 284 patients had sufficient 
data available for analysis. Clinicopathologic features are 
depicted in Table 1. Overall, 200 (70.4%) were treated with 
lLAD, 34 (12%) with eLAD, and 50 with sLAD (17.6%). 
The use of sLAD increased with time (Fig. 2). This was 
associated with an increase in lymph nodes harvested 
(median nodes harvested 13 vs 31 vs 39 for lLAD, eLAD, 
and sLAD, respectively). sLAD was significantly associated 
with a higher incidence of N2 and N3 status at RC com-
pared to lLAD and eLAD (p = 0.04). In subgroup analysis, 
the receipt of NAC in patients treated with sLAD was not 
associated with pN + status (OR 1.16, 95% CI 0.89–1.52).
Regarding perioperative outcomes, sLAD was associ-
ated with a blood loss of > 500 ml compared to lLAD and 
eLAD (OR 1.3, 95% CI 1.08–1.49, p = 0.003). However, 
it did not affect the number of intraoperative transfusions, 
operation time, or length of stay (all p > 0.05). On multivari-
able analysis which adjusted for the effect of age-adjusted 
Charlson comorbidity index (CCI), tumor stage, body mass 
index (BMI), and the use of enhanced recovery after surgery 
(ERAS) protocol, sLAD remained associated with a blood 
loss of > 500 ml (OR 1.21, 95% CI 1.02–1.44, p = 0.03).
Overall, 30- and 30–90-day complication rates were 
61.3% and 49.4%, respectively. Major complications 
occurred within 30 and 30–90 days in 75 (26.4%) and 41 
(14.4%) patients, respectively. The 30- and 30–90-day mor-
tality rates were 2.8% and 1.4%, respectively. A detailed 
distribution of postoperative complications is depicted in 
Tables 2 and s1. On logistic regression models, LAD tem-
plate was not associated with postoperative major compli-
cations (p > 0.05) (Table 2). A total of 49 (17.2%) patients 
experienced a postoperative ileus within 30 days. On 
univariable logistic regression analyses, sLAE was associ-
ated with a lower risk of ileus (OR 0.89, 95% CI 0.79–0.99, 
p = 0.04). However, on multivariable analyses which 
adjusted for the effects of patient age, BMI, and the use of 
ERAS protocol, this association disappeared.
In all, 11 (4%) patients were readmitted within 30 days 
and 50 (17.6%) within 30–90 days after RC. On logistic 
regression models, unscheduled hospitalization rates within 
30 and 30–90 days were not associated with the LAD tem-
plate used (p > 0.05) (Table 3).
On exploratory analyses, we investigated the associa-
tion of clinical features and performance scores with major 
complications and hospitalization. On logistic regression 
analysis, age (OR 1.03, 95% CI 1.01–1.06, p = 0.01) and CCI 
(OR 1.19, 95% CI 1.03–1.37, p = 0.01) were associated with 
30-day major complications. Moreover, CCI (OR 1.24, 95% 
CI 1.05–1.47, p < 0.001) was associated also with 90-day 
major complications. BMI was associated with 30-day read-
mission (OR 1.14, 95% CI 1.01–1.27, p = 0.02) (Table 4).
Discussion
We investigated perioperative complications and hospi-
talization rates associated with lLAD, eLAD, and sLAD 
using data originating from a tertiary referral center. We 
found that two-thirds of patients experienced any type of 
complication and one-third had at least one major complica-
tion within 30 days after RC. Our results corroborate those 
reported in retrospective studies and prospective trials [3, 
5, 9, 10, 13–15]. To our knowledge, this is the first study 
investigating the association of lLAD, eLAD, and sLAD 
with perioperative outcomes. We reject our null hypothesis, 
as we failed to observe an association between the extent of 
LAD template and perioperative complications. Importantly, 
the previous reports did not investigate the impact of LAD 
template on surgical morbidity. A retrospective multicenter 
series investigated the association of LAD with survival 
outcomes. Authors could not show a significant difference 
between eLAD and sLAD. However, no postoperative out-
comes were reported [9]. Results from the first RCT com-
paring lLAD vs sLAD did not show significant difference 
in terms of recurrence-free survival between groups. On 
exploratory analyses, mortality and major complications 
(Clavien–Dindo ≥ 3) occurring within 30 and 90 days did 
not differ between groups [10].
We found that re-hospitalization rates were lower than 
those reported in large series (19.6% vs > 40%) [16, 17]. 
However, the comparative data originate from population-
based databases including different hospitals. Indeed, data 
from high-volume tertiary care centers revealed similar re-
hospitalization rates compared to ours [3, 18].
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While clinicopathologic features and comorbidity indices 
have been associated with hospitalization [3, 18], studies 
investigating this association with LAD templates are miss-
ing. We filled this gap using logistic regression models.
Table 1  Clinicopathologic features and perioperative outcomes of 284 patients treated with radical cystectomy and lymphadenectomy (LAD) for 
clinically non-metastatic bladder cancer, stratified by LAD template
IQR interquartile range, BMI body mass index, STSM Soft tissue surgical margin, UUCS uretero–uretero-cutaneostomy, NAC neoadjuvant chemo-
therapy, NA not available
a No diversion necessary because of chronic hemodialysis
Limited LAD Extended LAD Super-extended LAD p
n 200 34 50
Age, median (IQR) 67 (61–74) 65 (62–73.7) 68 (57.5–75.7) 0.92
Male gender (%) 158 (79.0) 25 (73.5) 37 (74.0) 0.63
BMI, median (IQR) 25.8 (22.9–27.96) 26.4 (23.9–29.7) 25.9 (22.4–27.96) 0.26
Charlson comorbidity index, median (IQR) 5 (4–7) 6 (4.2–8) 5 (4–8) 0.22
Preoperative hydronephrosis, n (%) < 0.01
 No 41 (20.5) 12 (35.3) 32 (64.0)
 Yes 13 (6.5) 9 (26.5) 17 (34.0)
 NA 146 (73.0) 13 (38.2) 1 (2.0)
pT, n (%) 0.01
 NMIBC 47 (23.5) 9 (26.5) 14 (28.0)
 T0 1 (0.5) 1 (2.9) 5 (10.0)
 T2 57 (28.5) 8 (23.5) 11 (22.0)
 T3 62 (31.0) 10 (29.4) 17 (34.0)
 T4 33 (16.5) 6 (17.6) 3 (6.0)
pN, n (%) 0.04
 N0 143 (71.5) 25 (73.5) 33 (66.0)
 N1 23 (11.5) 4 (11.8) 3 (6.0)
 N2 33 (16.5) 4 (11.8) 10 (20.0)
 N3 1 (0.5) 1 (2.9) 4 (8.0)
Lymph nodes removed, median (IQR) 13 (7–22) 31 (13–37) 39 (25–52) < 0.01
STSM, n (%) 0.28
 R0 174 (87.0) 29 (85.3) 43 (86.0)
 R1 26 (13.0) 4 (11.8) 6 (12.0)
 Rx 0 (0.0) 1 (2.9) 1 (2.0)
Variant histology, n (%) < 0.01
 Absent 175 (87.5) 22 (64.7) 32 (64.0)
 Mixed 15 (7.5) 11 (32.4) 12 (24.0)
 Pure 6 (3.0) 1 (2.9) 4 (8.0)
 NA 4 (2.0) 0 (0.0) 2 (4.0)
Diversion, n (%) 0.03
 UUCS 13 (6.5) 1 (2.9) 1 (2.0)
 Colon conduit 4 (2.0) 0 (0.0) 0 (0.0)
 Ileum conduit 127 (63.5) 30 (88.2) 43 (86.0)
 Ileum neobladder 54 (27.0) 3 (8.8) 5 (10.0)
 No  diversiona 2 (1.0) 0 (0.0) 1 (2.0)
NAC (%) 2 (1.0) 2 (5.9) 21 (42.0) < 0.01
Days of hospital stay, median (IQR) 20 (16–25) 18 (15–20) 16.5 (13–25.7) 0.01
Transfusion rate, median (IQR) 1 (0–2) 0 (0–2) 1 (0–2) 0.71
Estimated blood loss (ml), median (IQR) 700 (400–1200) 700 (500–1225) 1000 (700–1200) 0.08
Operation time (min), median (IQR) 336 (281–402) 330 (295–360) 345 (295–370) 0.99
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We did not find any difference in operative times between 
different LAD templates. Retrospective series reported con-
troversial results [13, 19]. The operative time depends on 
the surgeon, different LAD templates, previous surgeries, 
and other factors affecting the surgical site; all of these may 
have influenced these results. We have adopted sLAD in 
more recent years, reflecting the improvement of the surgi-
cal technique and a change in surgical paradigm over the 
years. Although the sLAD cohort had higher blood loss, 
this was not associated with higher transfusion rates [13]. 
Various factors can affect blood loss such as comorbidities, 
surgical approach and technique, disease severity as well as 
measurement of blood loss. To our knowledge, no previous 
studies have reported on blood loss in patients who under-
went sLND.
LAD is an essential compound of RC necessary for accu-
rate staging and, potentially, for disease control [5]. A recent 
RCT form Germany highlighted this issue reporting a 2% 
rate of lymph-node metastases outside the lLAD [10]. In 
our series, four patients (8%) treated with sLAD had lymph-
node metastases outside the lLAD and eLAD template. 
These patients would have been, therefore, understaged if 
no sLAD would have been performed. Moreover, we found 
higher rates of pN3 compared to this trial (2.1% vs 0.5%). 
However, these results must be interpreted in the context 
of the retrospective design and the lack of pathologic re-
review. It is, however, true that our series includes patients 
with clinically more evolved disease than the German RCT.
Identification of preoperative risk factors for hospitaliza-
tion is of paramount importance for patients’ management 
and counseling. In line with the previous reports, we identi-
fied advanced age and high CCI to be associated with the 
risk of major postoperative complications [13, 14, 19]. How-
ever, these studies did not investigate the association of LAD 
A
B
Fig. 2  Distribution of lymphadenectomy templates (a) and pN status 
(b) over time in 284 patients treated with radical cystectomy for clini-











































































































































































































































































































































































































































126 World Journal of Urology (2020) 38:121–128
1 3
extent with outcomes. This is a relevant shortcoming, as 
omitting surgical steps can obviously influence perioperative 
outcomes. To overcome these limitations, we performed a 
detailed analysis of complications associated with different 
LADs and showed that a more extensive LAD is not associ-
ated with higher perioperative morbidity, while this is asso-
ciated with a better disease staging. Whether the extent of 
LAD is associated with cure rates and survival remains to be 
assessed in ongoing prospective RCTs (i.e., SWOG 1011).
Nevertheless, RC remains a procedure associated with 
high perioperative complication rates due to the procedure 
itself, patients’ comorbidities and tumor characteristics. It 
is, therefore, of paramount importance to balance potential 
benefits of a more extended LAD and counsel patients for a 
risk-adapted approach. In this context, one-fits-all approach 
using a unified template for all patients is not optimal and 
can be considered an overtreatment in a significant number 
of patients [6, 7]. There is an unmet need for better patient 
selection and development of clinical tool which may aid in 
Table 3  Distribution and logistic regression analysis for the association of hospitalization rates with the lymphadenectomy (LAD) template used 
in 284 patients treated with radical cystectomy for clinically non-metastatic bladder cancer
Hospitalizations within 30 days Hospitalizations within 30–90 days
N OR (95% CI) p N OR (95% CI) p
Limited LAD 6 (2.25%) Ref. 34 (13.1%) Ref.
Extended LAD 3 (1.13%) 1.06 (0.99–1.45) 0.1 4 (1.5%) 0.95 (0.81–1.11) 0.5
Super-extended LAD 2 (0.75%) 1.01 (0.95–1.08) 0.7 13 (5%) 1.5 (0.71–3.19) 0.2
Table 4  Logistic regression analyses investigating the association of clinical features with major postoperative complications (Clavien–
Dindo ≥ 3) and hospitalization in 284 patients treated with radical cystectomy for clinically non-metastatic bladder cancer
OR odds ratio, CI confidence interval, BMI body mass index, ASA American Society of Anesthesiologists, ECOG Eastern Cooperative Oncology 
Group, CCI Charlson comorbidity index; ERAS enhanced recovery after surgery
30-day major complications 30–90-day major complications
OR (95% CI) p OR (95% CI) p
Age 1.03 (1.01–1.06) 0.01 1.03 (0.99–1.07) 0.1
Male gender 1.4 (0.74–2.79) 0.3 1.49 (0.66–3.82) 0.4
BMI 1.04 (0.78–1.1) 0.2 1.05 (0.97–1.23) 0.2
ASA 1.35 (0.6–2.99) 0.5 1.65 (0.66–4.1) 0.3
ECOG 1.21 (0.63–2.26) 0.5 1.46 (0.71–2.88) 0.3
CCI 1.19 (1.03–1.37) 0.01 1.24 (1.05–1.47) < 0.01
ERAS 0.77 (0.21–2.23) 0.6 0.72 (0.11–2.69) 0.7
Diversion (no diversion or UUCS ref.)
 Conduit 1.42 (0.49–5.18) 0.5 3.52 (0.69–64.5) 0.2
 Neobladder 0.93 (0.27–3.69 0.9 1.49 (0.22–29.6) 0.7
30-day hospitalization 30-day hospitalization
OR (95% CI) p OR (95% CI) p
Age 1.00 (0.95–1.06) 0.9 1.01 (0.98–1.04) 0.5
Male gender 1.32 (0.33–8.82) 0.7 1.39 (0.66–3.23) 0.4
BMI 1.14 (1.01–1.27) 0.02 1.03 (0.96–1.1) 0.3
ASA 0.83 (0.08–6.14) 0.9 0.8 (0.3–1.99) 0.6
ECOG 2.39 (0.56–8.68) 0.2 1.08 (0.49–2.15) 0.8
CCI 1.13 (0.81–1.49) 0.4 1.13 (0.95–1.32) 0.1
ERAS 1.5 (0.08–8.58) 0.7 1.37 (0.37–4.01) 0.6
Diversion (no diversion or UUCS ref.)
 Conduit 0.34 (0.05–6.85) 0.3 3.89 (0.76–71.2) 0.2
 Neobladder 1.82 (0.28–35.7) 0.6 3.67 (0.64–69.5) 0.2
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the identification of patients who are more likely to benefit 
from a sLAD.
Despite its strengths, our study is not devoid of limita-
tions, which are mainly inherent to its retrospective design. 
The long time span of the study and missing sLAD in early 
years may have influenced results. Moreover, different sur-
geons over time may have also introduced additional bias. 
sLAD patients had higher rate of NAC which has been sug-
gestive to lead to more difficult dissection and a minimally 
higher complication rate [20]. Finally, other perioperative 
pathways that have shown to improve surgical outcomes, i.e., 
the ERAS protocol [21], were implemented in more recent 
patients treated mainly with sLAD, influencing, therefore, 
results.
Conclusions
Our data confirm that while sLAD leads to higher number 
of nodes removed and resulting higher nodal stage, it does 
not increase perioperative morbidity. Further studies should 
focus on the development of risk-adapted models to guide 
the choice of an individualized LAD template based on clin-
icopathologic characteristics and patient health status in a 
shared decision-making process with the patient.
Acknowledgements Open access funding provided by Medical Uni-
versity of Vienna.
Author contributions SFS and DA protocol/project development. DA 
data collection or management and data analysis. DA, MA, FS, KG, 
AH, PIK, and SFS manuscript writing/editing.
Compliance with ethical standards 
Conflict of interest Nothing to disclose.
Research involving human participants and/or animals and Informed 
consent Retrospective analysis, no informed consent needed.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Alfred Witjes J, Lebret T, Compérat EM et al (2016) Updated 
2016 EAU guidelines on muscle-invasive and metastatic blad-
der cancer. Eur Urol 71:462–475. https ://doi.org/10.1016/j.eurur 
o.2016.06.020
 2. Vazina A, Dugi D, Shariat SF et al (2004) Stage specific lymph 
node metastasis mapping in radical cystectomy specimens. J Urol 
171:1830–1834. https ://doi.org/10.1097/01.ju.00001 21604 .58067 
.95
 3. Woldu SL, Sanli O, Clinton TN, Lotan Y (2018) Validating the 
predictors of outcomes after radical cystectomy for bladder can-
cer. Cancer 34:1945. https ://doi.org/10.1002/cncr.31799 
 4. Abdollah F, Sun M, Schmitges J et al (2012) Stage-specific impact 
of pelvic lymph node dissection on survival in patients with non-
metastatic bladder cancer treated with radical cystectomy. BJU Int 
109:1147–1154. https ://doi.org/10.1111/j.1464-410X.2011.10482 
.x
 5. Bruins HM, Veskimäe E, Hernández V et al (2014) The impact of 
the extent of lymphadenectomy on oncologic outcomes in patients 
undergoing radical cystectomy for bladder cancer: a systematic 
review. Eur Urol 66:1065–1077. https ://doi.org/10.1016/j.eurur 
o.2014.05.031
 6. Jensen JB, Ulhøi BP, Jensen KME (2010) Lymph node mapping 
in patients with bladder cancer undergoing radical cystectomy 
and lymph node dissection to the level of the inferior mesenteric 
artery. BJU Int 106:199–205. https ://doi.org/10.1111/j.1464-
410X.2009.09118 .x
 7. Leissner J, Ghoneim MA, Abol-Enein H et al (2004) Extended 
radical lymphadenectomy in patients with urothelial bladder can-
cer: results of a prospective multicenter study. J Urol 171:139–
144. https ://doi.org/10.1097/01.ju.00001 02302 .26806 .fb
 8. Dorin RP, Daneshmand S, Eisenberg MS et al (2011) Lymph node 
dissection technique is more important than lymph node count 
in identifying nodal metastases in radical cystectomy patients: 
a comparative mapping study. Eur Urol 60:946–952. https ://doi.
org/10.1016/j.eurur o.2011.07.012
 9. Zehnder P, Studer UE, Skinner EC et al (2011) Super extended 
versus extended pelvic lymph node dissection in patients undergo-
ing radical cystectomy for bladder cancer: a comparative study. J 
Urol 186:1261–1268. https ://doi.org/10.1016/j.juro.2011.06.004
 10. Gschwend JE, Heck MM, Lehmann J et  al (2018) Extended 
versus limited lymph node dissection in bladder cancer patients 
undergoing radical cystectomy: survival results from a prospec-
tive, randomized trial. Eur Urol. https ://doi.org/10.1016/j.eurur 
o.2018.09.047
 11. Dindo D, Demartines N, Clavien P-A (2004) Classification of 
surgical complications: a new proposal with evaluation in a cohort 
of 6336 patients and results of a survey. Ann Surg 240:205–213
 12. Rink M, Fajkovic H, Cha EK et al (2012) Death certificates are 
valid for the determination of cause of death in patients with upper 
and lower tract urothelial carcinoma. Eur Urol 61:854–855. https 
://doi.org/10.1016/j.eurur o.2011.12.055
 13. Brössner C, Pycha A, Toth A et al (2004) Does extended lymphad-
enectomy increase the morbidity of radical cystectomy? BJU Int 
93:64–66
 14. Isbarn H, Jeldres C, Zini L et al (2009) A population based assess-
ment of perioperative mortality after cystectomy for bladder can-
cer. J Urol 182:70–77. https ://doi.org/10.1016/j.juro.2009.02.120
 15. Shabsigh A, Korets R, Vora KC et al (2009) Defining early mor-
bidity of radical cystectomy for patients with bladder cancer using 
a standardized reporting methodology. Eur Urol 55:164–174. https 
://doi.org/10.1016/j.eurur o.2008.07.031
 16. Stitzenberg KB, Chang Y, Smith AB, Nielsen ME (2015) 
Exploring the burden of inpatient readmissions after major can-
cer surgery. J Clin Oncol 33:455–464. https ://doi.org/10.1200/
JCO.2014.55.5938
 17. Joice GA, Chappidi MR, Patel HD et al (2018) Hospitalisation 
and readmission costs after radical cystectomy in a nationally rep-
resentative sample: does urinary reconstruction matter? BJU Int 
96:74–1024. https ://doi.org/10.1111/bju.14448 
 18. Stimson CJ, Chang SS, Barocas DA et al (2010) Early and late 
perioperative outcomes following radical cystectomy: 90-day 
128 World Journal of Urology (2020) 38:121–128
1 3
readmissions, morbidity and mortality in a contemporary series. 
J Urol 184:1296–1300. https ://doi.org/10.1016/j.juro.2010.06.007
 19. Jensen JB, Ulhoi BP, Jensen KM-E (2012) Extended versus lim-
ited lymph node dissection in radical cystectomy: impact on recur-
rence pattern and survival. Int J Urol 19:39–47. https ://doi.org/10
.1111/j.1442-2042.2011.02887 .x
 20. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant 
chemotherapy plus cystectomy compared with cystectomy alone 
for locally advanced bladder cancer. N Engl J Med 349:859–866. 
https ://doi.org/10.1056/NEJMo a0221 48
 21. Azhar RA, Bochner B, Catto J et al (2016) Enhanced recovery 
after urological surgery: a contemporary systematic review of out-
comes, key elements, and research needs. Eur Urol 70:176–187. 
https ://doi.org/10.1016/j.eurur o.2016.02.051
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
